IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, as detailed in the company press release
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, as detailed in the company press release. All of the shares of common stock are being offered by IDEAYA. In addition, IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. The offering is expected to close on May 28, 2019, subject to the satisfaction of customary closing conditions.
Latham & Watkins LLP represents IDEAYA Biosciences, Inc. in the offering with a corporate team led by Silicon Valley partners Mark Roeder and Ben Potter with Silicon Valley associates Adam Whitaker, Alexander White and Madelyn Tarr, and Orange County associate Eric Hanzich. Advice was also provided on licensing matters by Silicon Valley/San Diego partner Christopher Hazuka with Silicon Valley associate Peggy Ni; on FDA regulatory matters by Washington, D.C. partner John Manthei with associates Eitan Bernstein and Robert Canning; on benefits and compensation matters by Silicon Valley partner James Metz with Los Angeles associate Megan Ampe; and on tax matters by San Francisco partner Grace Lee with Silicon Valley associate Mi Zhou.
